PUBLISHER: DelveInsight | PRODUCT CODE: 1854964
PUBLISHER: DelveInsight | PRODUCT CODE: 1854964
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer (EGFR-NSCLC)- Epidemiology Forecast - 2034
Key Highlights:
- The total incident population of NSCLC in the 7MM expected to rise from 537,675 in 2024, due to population growth, an aging demographic, and the increasing prevalence of major risk factors such as smoking and air pollution, which will place a significant burden on both patients and healthcare systems globally.
- In histology-specific cases, adenocarcinoma accounts for highest number of cases, i.e., approximately 57% followed by squamous cell carcinoma.
- EGFR-mutated NSCLC is more prevalent in Asian countries such as Japan, with mutation rates estimated at 45%, compared to 15% in Western countries. Majorly due to genetic predisposition, lower smoking rates among Asian patients, and distinct environmental factors that contribute to a higher likelihood of oncogenic driver mutations.
- In 2024, EGFR Exon 19 deletions contributed to the highest number of cases, nearly 10,000 in the EGFR NSCLC in the US.
DelveInsight's "Epidermal Growth Factor Receptor Non-small Cell Lung Cancer (EGFR-NSCLC)- Epidemiology Forecast - 2034" report delivers an in-depth understanding of Epidermal Growth Factor Receptor Non-small Cell Lung Cancer (EGFR-NSCLC), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan..
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer Understanding
EGFR-NSCLC Overview
EGFR is a protein in cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer. There are different types of EGFR mutations, including deletions or insertions and point mutations. In test results, individuals may be identified as having an EGFR 19 deletion or an EGFR L858R point mutation, which are the most common types of EGFR mutations. These mutations are typically treated the same way. Amongst the EGFR mutations that are tested for in lung cancer, a few rare types are treated differently than the more common EGFR mutations. The major example of this in lung cancer is EGFR exon 20 insertions. This is a type of EGFR mutation that does not respond to the typical treatment for EGFR-positive lung cancer, which are called tyrosine kinase inhibitors, or TKIs.
EGFR-NSCLC Diagnosis
In general, there are two ways to detect EGFR mutations. The best way is through comprehensive next-generation sequencing (NGS). This type of testing places tissue from a patient's tumor (gathered from a biopsy) in a machine that looks for a large number of possible biomarkers at one time. There may be some situations where a patient cannot undergo the biopsy needed to perform NGS, so liquid biopsy is recommended. A liquid biopsy can look for certain biomarkers in a patient's blood.
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer Epidemiology
The EGFR-NSCLC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as Total Incident Cases of NSCLC, Gender-specific Cases of NSCLC, Age-specific Cases of NSCLC, Total Incident Cases of NSCLC by Histology, Total Incident Cases of NSCLC by Stage, and Total Cases of EGFR-NSCLC, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
- The total number of incident cases of NSCLC in the United States was nearly 204,800 in 2024.
- The total number of cases in EU4 and the UK for EGFR-NSCLC was estimated to be nearly 211,000 cases in 2024.
- The total number of cases of EGFR Exon 20 insertion mutations in Japan was estimated to be nearly 5,000 in 2024.
- Males face a higher lifetime risk of developing lung cancer and experience greater mortality compared to females. This disparity is partly attributed to lifestyle factors, as men are more likely to engage in cigarette smoking, alcohol consumption, high-calorie diets, and drug use, all of which elevate lung cancer risk.
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer Report Insights
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer Report Insights
- Patient population
- Country-wise epidemiology distribution
Epidermal Growth Factor Receptor Non-small Cell Lung Cancer Report Key Strengths
- Ten-year Forecast
- 7MM Coverage
- EGFR-NSCLC Epidemiology Segmentation
FAQs:
- What are the disease risks, burdens, and unmet needs of EGFR-NSCLC? What will be the growth opportunities across the 7MM concerning the patient population with EGFR-NSCLC?
- What is the historical and forecasted EGFR-NSCLC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- To understand the gender-specific radiation-induced esophagitis prevalent cases in varying geographies over the coming years.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of EGFR-NSCLC
4. Epidemiology Forecast Methodology
5. EGFR-NSCLC Overview at a Glance
- 5.1. Patient Share (%) of EGFR-NSCLC in 2024 in the 7MM
- 5.2. Patient Share (%) of EGFR-NSCLC in 2034 in the 7MM
6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Structure and Mechanism of EGFR
- 6.3. Types of EGFR Mutation in NSCLC
- 6.4. Risk Factors Associated With EGFR-mutated NSCLC
- 6.5. Diagnosis
- 6.5.1. Biomarker Testing for EGFR Mutation
- 6.5.2. Diagnosis Algorithm of EGFR
- 6.5.3. Diagnosis Guidelines
7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Incident Cases of NSCLC in the 7MM
- 7.4. United States
- 7.4.1. Total Incident Cases of NSCLC in the United States
- 7.4.2. Gender-specific Cases of NSCLC in the United States
- 7.4.3. Age-specific Cases of NSCLC in the United States
- 7.4.4. Total Incident Cases of NSCLC by Histology in the United States
- 7.4.5. Total Incident Cases of NSCLC by Stage in the United States
- 7.4.6. Total Cases of EGFR-NSCLC in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Incident Cases of NSCLC in EU4 and the UK
- 7.5.2. Gender-specific Cases of NSCLC in EU4 and the UK
- 7.5.3. Age-specific Cases of NSCLC in EU4 and the UK
- 7.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
- 7.5.5. Total Incident Cases of NSCLC by Stage in EU4 and the UK
- 7.5.6. Total Incident Cases of EGFR-NSCLC by biomarker in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Incident Cases of NSCLC in Japan
- 7.6.2. Gender-specific Cases of NSCLC in Japan
- 7.6.3. Age-specific Cases of NSCLC in Japan
- 7.6.4. Total Incident Cases of NSCLC by Histology in Japan
- 7.6.5. Total Incident Cases of NSCLC by Stage in Japan
- 7.6.6. Total Cases of EGFR-NSCLC in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: Summary of EGFR-NSCLC Epidemiology (2024-2034)
- Table 2: Types of EGFR Mutation
- Table 3: EGFR Biomarker Epidemiology
- Table 4: Total Incident Cases of NSCLC in the 7MM (2020-2034)
- Table 5: Total Incident Cases of NSCLC in the United States (2020-2034)
- Table 6: Gender-specific Cases of NSCLC in the United States (2020-2034)
- Table 7: Age-specific Cases of NSCLC in the United States (2020-2034)
- Table 8: Total Incident Cases of NSCLC by Histology in the United States (2020-2034)
- Table 9: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2020-2034)
- Table 10: Total Incident Cases of Advanced/Metastatic NSCLC in the United States (2020-2034)
- Table 11: Total Cases of EGFR-NSCLC in the United States (2020-2034)
- Table 12: Total Incident Cases of NSCLC in EU4 and the UK (2020-2034)
- Table 13: Gender-specific Cases of NSCLC in EU4 and the UK (2020-2034)
- Table 14: Age-specific Cases of NSCLC in EU4 and the UK (2020-2034)
- Table 15: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2020-2034)
- Table 16: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2020-2034)
- Table 17: Total Incident Cases of Advanced/Metastatic NSCLC in the EU4 and the UK (2020-2034)
- Table 18: Total Incident Cases of EGFR-NSCLC by biomarker in EU4 and the UK (2020-2034)
- Table 19: Total Cases of EGFR-NSCLC in EU4 and the UK (2020-2034)
- Table 20: Total Incident Cases of NSCLC in Japan (2020-2034)
- Table 21: Gender-specific Cases of NSCLC in Japan (2020-2034)
- Table 22: Age-specific Cases of NSCLC in Japan (2020-2034)
- Table 23: Total Incident Cases of NSCLC by Histology in Japan (2020-2034)
- Table 24: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2020-2034)
- Table 25: Total Incident Cases of Advanced/Metastatic NSCLC in Japan (2020-2034)
- Table 26: Total Cases of EGFR-NSCLC in Japan (2020-2034)
List of Figures
- Figure 1: Mechanism of Action of EGFR
- Figure 2: Types of EGFR Mutation in NSCLC
- Figure 3: Risk Factors Associated With EGFR-mutated NSCLC
- Figure 4: Diagnosis Algorithm of EGFR
- Figure 5: Tumor Biomarker Testing Rate
- Figure 6: Total Incident Cases of NSCLC in the 7MM (2020-2034)
- Figure 7: Total Incident Cases of NSCLC in the United States (2020-2034)
- Figure 8: Gender-specific Cases of NSCLC in the United States (2020-2034)
- Figure 9: Age-specific Cases of NSCLC in the United States (2020-2034)
- Figure 10: Total Incident Cases of NSCLC by Histology in the United States (2020-2034)
- Figure 11: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2020-2034)
- Figure 12: Total Cases of EGFR-NSCLC in the United States (2020-2034)
- Figure 13: Total Incident Cases of NSCLC in EU4 and the UK (2020-2034)
- Figure 14: Gender-specific Cases of NSCLC in EU4 and the UK (2020-2034)
- Figure 15: Age-specific Cases of NSCLC in EU4 and the UK (2020-2034)
- Figure 16: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2020-2034)
- Figure 17: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2020-2034)
- Figure 18: Total Incident Cases of EGFR-NSCLC by biomarker in EU4 and the UK (2020-2034)
- Figure 19: Total Incident Cases of NSCLC in Japan (2020-2034)
- Figure 20: Gender-specific Cases of NSCLC in Japan (2020-2034)
- Figure 21: Age-specific Cases of NSCLC in Japan (2020-2034)
- Figure 22: Total Incident Cases of NSCLC by Histology in Japan (2020-2034)
- Figure 23: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2020-2034)
- Figure 24: Total Cases of EGFR-NSCLC in Japan (2020-2034)
